Eterna Therapeutics Inc. has entered into a securities purchase agreement with accredited investors to sell around $9.2 million in senior convertible promissory notes and warrants. These warrants allow for the purchase of approximately 9.58 million shares of common stock. The private placement transaction was priced at-the-market under Nasdaq rules. The company anticipates an initial closing with proceeds of about $7.8 million on December 15, 2023, and the remaining funds by January 15, 2023.